ENDPOINTS NEWS55m
Louisiana's Bill Cas­sidy named next chair of Sen­ate health com­mit­tee
Sen. Bill Cassidy (R-LA) will take over the Senate Health, Education, Labor, and Pensions Committee when the GOP gets control ...
ENDPOINTS NEWS1h
Eu­ro­pean Com­mis­sion seeks bio­phar­ma feed­back on No­vo-Catal­ent deal — re­port
The Eu­ro­pean Com­mis­sion is ask­ing bio­phar­ma and man­u­fac­tur­ing com­pa­nies about their re­ac­tion to No­vo ...
ENDPOINTS NEWS2h
New Zealand clears first clin­i­cal tri­al of epi­ge­net­ic edit­ing for he­pati­tis B
New Zealand approved Tune Therapeutics' TUNE-401, an epigenetic editing therapy for chronic hepatitis B, for human trials.
ENDPOINTS NEWS2h
No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly
No­vo Nordisk said Thurs­day that it plans to even­tu­al­ly halt all of its hu­man in­sulin pen pro­duc­tion glob­al­ly, ...
ENDPOINTS NEWS2h
Lon­za ex­pands bio­con­ju­gates fac­to­ry; WuXi Bio adds ca­pac­i­ty in Ger­many
Lonza, WuXi Biologics, and Baxter Healthcare announce facility expansions and updates. Repligen reports revenue growth, while ...
ENDPOINTS NEWS3h
BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots
The global pharma company whose name rhymes with the capital of China wants people to know that it is not in fact a Chinese ...
ENDPOINTS NEWS3h
As blue­bird projects more com­mer­cial de­mand, the biotech con­tin­ues to seek cash
Bluebird reports 17 people with sickle cell disease started receiving Lyfgenia gene therapy, with 35 starting Zynteglo for ...
ENDPOINTS NEWS4h
Mer­ck KGaA’s life sci­ence unit is still feel­ing the Covid de­mand de­cline
Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...
ENDPOINTS NEWS6h
Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da
Sum­mit Ther­a­peu­tics and its Chi­nese part­ner Ake­so have a few com­peti­tors now.
ENDPOINTS NEWS13h
FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope
The FDA has cleared PTC Ther­a­peu­tics’ gene ther­a­py for AADC de­fi­cien­cy, an ul­tra-rare dis­ease that im­pacts the ...
ENDPOINTS NEWS23h
Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field
The amylin field is heating up ahead of Novo Nordisk's much-anticipated CagriSema readout later this year. On Wednesday, ...
ENDPOINTS NEWS21h
Drug in­spec­tor at­tri­tion leads to 'many few­er' checks than 2016 peak, GAO says
The GAO report highlights FDA's drug inspection program challenges, including 36% fewer inspections in 2023 compared to 2019 ...